Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Enzymatica

Enzymatica

Enzyme-based medical products

Enzymatica is based in Lund, Sweden, and sells medical devices against infectious diseases. The company's first product is ColdZyme® Munspray, which is marketed for cold virus prophylaxis and anti-cold virus therapeutic.

Double-digit sales growth with most markets in the world, including many in Europe, not yet commercialized.

The main risk is that the company might not be able to meet its future liquidity needs. New entrants to the market, changes in regulation governing medical devices, and R&D failures could also impact the long-term outlook.

SEKm 2020 2021e 2022e
Sales 111 74 146
Sales growth (%) 81,5 -33,8 97,9
EBITDA -5 -37 0
EBITDA margin (%) -4,5 -49,9 0,3
EBIT adj -12 -44 -7
EBIT adj margin (%) -10,8 -59,5 -4,5
Pretax profit -13 -45 -9
EPS rep -0,09 -0,31 -0,06
EPS growth (%) 67,7 -232 79,4
EPS adj -0,09 -0,31 -0,06
DPS 0 0 0
EV/EBITDA (x) -534 -38,8 3083,2
EV/EBIT adj (x) -220,5 -32,5 -218,2
P/E (x) -202 -33,1 -160,8
P/E adj (x) -202 -33,1 -160,8
EV/sales (x) 23,9 19,4 9,9
FCF yield (%) -0,6 -2,1 -1,2
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 2,2 1,3 -66,3
Lease adj. FCF yield (%) -0,6 -2,1 -1,2
Lease adj. ND/EBITDA 2,2 1,3 -66,3
SEKm 2020 2021e 2022e
Sales 111 74 146
COGS -35 -29 -51
Gross profit 76 45 95
Other operating items -81 -81 -95
EBITDA -5 -37 0
Depreciation on tangibles -1 -1 -1
Depreciation on intangibles -6 -6 -6
EBITA -12 -44 -7
Goodwill impairment charges 0 0 0
Other impairment and amortisation 0 0 0
EBIT -12 -44 -7
Other financial items 0 0 0
Net financial items -1 -2 -3
Associated income 0 0 0
Other EO items 0 0 0
Pretax profit -13 -45 -9
Tax 0 1 0
Net profit -13 -45 -9
Minority interest 0 0 0
Net profit discontinued 0 0 0
Net profit to shareholders -13 -45 -9
EPS -0,09 -0,31 -0,06
EPS Adj -0,09 -0,31 -0,06
Total extraordinary items after tax 0 0 0
Tax rate (%) 1,2 -1,7 -3
Gross margin (%) 68,3 60,6 65,3
EBITDA margin (%) -4,5 -49,9 0,3
EBITA margin (%) -10,8 -59,5 -4,5
EBIT margin (%) -10,8 -59,5 -4,5
Pretax margin (%) -11,7 -61,6 -6,5
Net margin (%) -11,9 -60,6 -6,3
Growth rates Y/Y 2020 2021 2022
Sales growth (%) 81,5 -33,8 97,9
EBITDA growth (%) 85,6 -637,4 101,3
EBIT growth (%) 71 -263,2 84,9
Net profit growth (%) 67,7 -237,2 79,4
EPS growth (%) 67,7 -232 79,4
Profitability 2020 2021 2022
ROE (%) -11,7 -39,2 -7,9
ROE Adj (%) -11,7 -39,2 -7,9
ROCE (%) -7,3 -33,8 -5
ROCE Adj(%) -7,3 -33,8 -5
ROIC (%) -12,9 -51 -8,3
ROIC Adj (%) -12,9 -51 -8,3
Adj earnings numbers 2020 2021 2022
EBITDA Adj -5 -37 0
EBITDA Adj margin (%) -4,5 -49,9 0,3
EBITA Adj -12 -44 -7
EBITA Adj margin (%) -10,8 -59,5 -4,5
EBIT Adj -12 -44 -7
EBIT Adj margin (%) -10,8 -59,5 -4,5
Pretax profit Adj -13 -45 -9
Net profit Adj -13 -45 -9
Net profit to shareholders Adj -13 -45 -9
Net Adj margin (%) -11,9 -60,6 -6,3
Depreciation and amortisation -7 -7 -7
Of which leasing depreciation 0 0 0
EO items 0 0 0
Impairment and PPA amortisation 0 0 0
EBITDA lease Adj -5 -37 0
EBITDA lease Adj margin (%) -4,5 -49,9 0,3
Leasing payments 0 0 0
SEKm 2020 2021e 2022e
EBITDA -5 -37 0
Net financial items -1 -2 -3
Paid tax 0 1 0
Non-cash items 0 0 0
Cash flow before change in WC -6 -37 -2
Change in WC -5 9 -12
Operating cash flow -11 -29 -14
CAPEX tangible fixed assets -5 -2 -4
CAPEX intangible fixed assets 0 0 0
Acquisitions and disposals 0 0 0
Free cash flow -15 -31 -18
Dividend paid 0 0 0
Share issues and buybacks 3 59 0
Other non cash items -16 9 1
Decrease in net IB debt -14 -21 11
Balance Sheet (SEKm) 2020 2021 2022
Goodwill 63 63 63
Indefinite intangible assets 0 0 0
Definite intangible assets 15 15 16
Tangible fixed assets 10 12 15
Other fixed assets 2 2 2
Fixed assets 91 88 89
Inventories 10 7 14
Receivables 37 16 25
Other current assets 0 0 0
Cash and liquid assets 24 61 44
Total assets 162 172 171
Shareholders equity 107 121 112
Minority 0 0 0
Total equity 107 121 112
Long-term debt 2 2 2
Pension debt 0 0 0
Convertible debt 0 0 0
Deferred tax 0 0 0
Other long-term liabilities 0 0 0
Short-term debt 13 13 13
Accounts payable 14 9 18
Other current liabilities 27 27 27
Total liabilities and equity 162 172 171
Net IB debt -11 -48 -31
Net IB debt excl. pension debt -11 -48 -31
Capital invested 96 73 81
Working capital 7 -13 -6
EV breakdown 2020 2021 2022
Market cap. diluted (m) 2671 1474 1474
Net IB debt Adj -11 -48 -31
Market value of minority 0 0 0
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity 0 0 0
EV 2660 1426 1443
Capital efficiency (%) 2020 2021 2022
Total assets turnover (%) 71,8 44,1 84,9
Capital invested turnover (%) 117,2 174,4 180,9
Capital employed turnover (%) 90 153,8 169,1
Inventories / sales (%) 7,8 7,4 8,3
Customer advances / sales (%) 0 0 0
Payables / sales (%) 10,9 9,8 11
Working capital / sales (%) 4,6 -4 -6,6
Financial risk and debt service 2020 2021 2022
Net debt / equity (%) -10,2 -39,5 -27,8
Net debt / market cap (%) -0,6 -3,2 -2,1
Equity ratio (%) 65,8 70,5 65,2
Net IB debt adj. / equity (%) -10,2 -39,5 -27,8
Current ratio (%) 134,1 172,7 143,3
EBITDA / net interest (%) -498,1 -2427,6 16,5
Net IB debt / EBITDA (%) 218,2 130,1 -6628,1
Interest cover (%) -226,4 -2303,2 -233,2
Lease liability amortisation 0 0 0
Other intangible assets 15 11 9
Right-of-use asset 0 0 0
Total other fixed assets 2 2 2
Leasing liability 0 0 0
Total other long-term liabilities 0 0 0
Net IB debt excl. leasing -11 -48 -31
Net IB debt / EBITDA lease Adj (%) 218,2 130,1 -6628,1
SEKm 2020 2021e 2022e
P/E -202 -33,1 -160,8
EV/sales 23,91 19,37 9,91
EV/EBITDA -534 -38,8 3083,2
EV/EBITA -220,5 -32,5 -218,2
EV/EBIT -220,5 -32,5 -218,2
Dividend yield (%) 0 0 0
FCF yield (%) -0,6 -2,1 -1,2
P/BVPS 25,04 12,19 13,19
P/BVPS Adj 95,13 31,7 37,38
P/E Adj -202 -33,1 -160,8
EV/EBITDA Adj -534 -38,8 3083,2
EV/EBITA Adj -220,5 -32,5 -218,2
EV/EBIT Adj -220,5 -32,5 -218,2
EV/cap. employed 21,9 10,5 11,4
Investment ratios 2020 2021 2022
Capex / sales 4,3 2,8 2,8
Capex / depreciation 68,3 29,6 58,6
Capex tangibles / tangible fixed assets 47,1 18,2 27,9
Capex intangibles / definite intangibles 0 0 0
Depreciation on intangibles / definite intangibles 40,7 55,8 68,6
Depreciation on tangibles / tangibles 8,1 7,2 5,6
Shares outstanding adj. 143 145 145
Fully diluted shares Adj 143 145 145
EPS -0,09 -0,31 -0,06
Dividend per share Adj 0 0 0
EPS Adj -0,09 -0,31 -0,06
BVPS 0,75 0,83 0,77
BVPS Adj 0,2 0,32 0,27
Net IB debt / share -0,1 -0,3 -0,2
Share price 13,26 10,16 10,16
Market cap. (m) 1893 1474 1474
Valuation 2020 2021 2022
Lease adj. FCF yield (%) -0,6 -2,1 -1,2

Equity research

Read earlier research

Media

Enzymatica - Company presentation with Chairman of the Board Bengt Baron
Enzymatica - Company presentation with CEO Fredrik Lindberg

Main shareholders - Enzymatica

Main shareholders Share capital % Voting shares % Verified
Mats K Andersson 21.0 % 21.0 % 9 Jun 2021
Håkan Roos (RoosGruppen) 12.0 % 12.0 % 30 Jun 2021
Björn Algkvist 10.1 % 10.1 % 30 Jun 2021
Gudmundur Palmasson 5.4 % 5.4 % 31 Mar 2021
Agusta Gudmundsdottir 3.6 % 3.6 % 31 Dec 2020
Fortus Hf 3.3 % 3.3 % 30 Jun 2021
AB Possessor 2.5 % 2.5 % 30 Jun 2021
Avanza Pension 2.0 % 2.0 % 30 Jun 2021
Nordnet Pensionsförsäkring 1.9 % 1.9 % 30 Jun 2021
Ulf Wiinberg 1.3 % 1.3 % 30 Jun 2021
Source: Holdings by Modular Finance AB

Insider list - Enzymatica

Name Quantity Code Date
Ulf Blom + 41 200 BUY 2 Sep 2021
Ulf Blom - 41 200 Redemp 2 Sep 2021
Ulf Blom - 40 000 Redemp 2 Sep 2021
Ulf Blom + 41 200 Redemp 2 Sep 2021
Kristoffer Ahlerup + 1 000 BUY 9 Aug 2021
Bengt Baron + 40 000 BUY 4 Aug 2021
Ulf Blom - 40 000 SELL 4 Aug 2021
Bengt Baron + 10 000 BUY 20 Jul 2021
Bengt Baron + 5 500 BUY 20 Jul 2021
Bengt Baron + 10 000 BUY 19 Jul 2021

Show More